Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Sales (2020 - 2025)

Historic Return on Sales for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 2.86%.

  • C4 Therapeutics' Return on Sales fell 12600.0% to 2.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.96%, marking a year-over-year decrease of 8200.0%. This contributed to the annual value of 2.96% for FY2024, which is 34200.0% up from last year.
  • Per C4 Therapeutics' latest filing, its Return on Sales stood at 2.86% for Q3 2025, which was down 12600.0% from 4.03% recorded in Q2 2025.
  • C4 Therapeutics' Return on Sales' 5-year high stood at 0.78% during Q4 2021, with a 5-year trough of 13.48% in Q2 2023.
  • Its 5-year average for Return on Sales is 5.16%, with a median of 3.64% in 2025.
  • As far as peak fluctuations go, C4 Therapeutics' Return on Sales plummeted by -122500bps in 2022, and later soared by 120100bps in 2024.
  • Over the past 5 years, C4 Therapeutics' Return on Sales (Quarter) stood at 0.78% in 2021, then tumbled by -1571bps to 13.03% in 2022, then rose by 18bps to 10.66% in 2023, then soared by 37bps to 6.68% in 2024, then surged by 57bps to 2.86% in 2025.
  • Its Return on Sales stands at 2.86% for Q3 2025, versus 4.03% for Q2 2025 and 3.64% for Q1 2025.